CFDE Data Portal | Search FCF1P5

	Label	Description
	FCF1P5 Gene (Entity type)	ENSG00000220392 - FCF1 pseudogene 5
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 9 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 0 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE224131 MAFB knockdown Macrophage Colony-Stimulating Factor 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GPR22 IDG GPCR ARCHS4 coexpression Gene Set (Entity type)	A Gene Set from IDG
	GTEx BloodVessel 20-29 vs 70-79 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Breast 20-29 vs 50-59 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Pituitary 20-29 vs 60-69 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Breast 20-29 vs 60-69 Up Gene Set (Entity type)	A Gene Set from GTEx

FCF1P5

ENSG00000220392 - FCF1 pseudogene 5

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 9 v 2 human dn

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 0 v 5 human up

A Gene Set from LINCS

GSE224131 MAFB knockdown Macrophage Colony-Stimulating Factor 2 v 1 human dn

A Gene Set from LINCS

GPR22 IDG GPCR ARCHS4 coexpression

A Gene Set from IDG

GTEx BloodVessel 20-29 vs 70-79 Up

A Gene Set from GTEx

GTEx Breast 20-29 vs 50-59 Up

A Gene Set from GTEx

GTEx Pituitary 20-29 vs 60-69 Up

A Gene Set from GTEx

GTEx Breast 20-29 vs 60-69 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.